Copyright
©The Author(s) 2016.
World J Gastroenterol. Aug 21, 2016; 22(31): 7030-7045
Published online Aug 21, 2016. doi: 10.3748/wjg.v22.i31.7030
Published online Aug 21, 2016. doi: 10.3748/wjg.v22.i31.7030
Class | Drug | Effect on HEV replication | Clinical use |
Calcineurin inhibitors | Cyclosporine, tacrolimus | Stimulates HEV replication with increase in HEV load and promotes HEV persistence | Reduce dose |
mTOR inhibitors | Rapamycin, everolimus | Stimulates HEV replication with increase in HEV load | Reduce dose |
Antimetabolite immunosuppressant | Mycophenolate mofetil | Inhibits HEV replication and helps HEV clearance | Continue the drug |
Guanosine analog | Ribavirin | Inhibits HEV replication and causes HEV clearance | Primary drug for therapy |
Cytokines | Pegylated interferon α | Inhibits HEV replication and causes HEV clearance | Indicated if Ribavirin therapy fails |
Nucleotide analog | Sofosbuvir | Inhibits HEV replication in vitro | Unclear, clinical trials indicated |
- Citation: Khuroo MS, Khuroo MS, Khuroo NS. Hepatitis E: Discovery, global impact, control and cure. World J Gastroenterol 2016; 22(31): 7030-7045
- URL: https://www.wjgnet.com/1007-9327/full/v22/i31/7030.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i31.7030